Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside

Authors

  • Rosalba Mansi Division of Radiopharmaceutical Chemistry, University Hospital Basel, University of Basel, CH-4031 Basel, Switzerland
  • Melpomeni Fani Division of Radiopharmaceutical Chemistry, University Hospital Basel, University of Basel, CH-4031 Basel, Switzerland;, Email: melpomeni.fani@usb.ch

DOI:

https://doi.org/10.2533/chimia.2021.500

Keywords:

Clinical translation, Exendin-4, Minigastrin, Somatostatin, Theranostics

Abstract

Radiolabeled peptides can deliver radiation selectively to tumors via targeting peptide receptors that are overexpressed on the surface of cancer cells. The radiation is used either for detection (imaging) or for destruction (therapy) of these tumors. The Division of Radiopharmaceutical Chemistry at the University Hospital Basel has conducted pioneering work on the development of peptide-based radiopharmaceuticals. Our research covers the entire spectrum of such developments, from bench-to-bedside, and it is illustrated in this article by selective cases.

Downloads

Published

2021-06-30

How to Cite

[1]
R. Mansi, M. Fani, Chimia 2021, 75, 500, DOI: 10.2533/chimia.2021.500.